Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2219565 | 1.00 | CES2 (0.50) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL2215864 | 0.91 | FAAH (0.56) | MEN1FAAHKMT2AMAPT | |
| SCHEMBL2218313 | 0.91 | FAAH (0.56) | MEN1FAAHKMT2AMAPT | |
| SCHEMBL2216417 | 0.87 | KDM4E (0.59) | MEN1FAAHKMT2A | |
| SCHEMBL6658822 | 0.82 | SPHK1 (0.52) | CES2MEN1KMT2AMAPT | |
| SCHEMBL6660873 | 0.82 | SPHK1 (0.52) | CES2MEN1KMT2AMAPT | |
| SCHEMBL6662704 | 0.82 | SPHK1 (0.52) | CES2MEN1KMT2AMAPT | |
| SCHEMBL6657792 | 0.82 | SPHK1 (0.52) | CES2MEN1KMT2AMAPT | |
| SCHEMBL6657533 | 0.82 | SPHK1 (0.52) | CES2MEN1KMT2AMAPT | |
| SCHEMBL6658154 | 0.82 | SPHK1 (0.52) | CES2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428448-B2 | Compounds and methods of treating obesity | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-16 | — | — | US | disclosed |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) | 2011-07-21 | — | — | US | disclosed |
| EP-2262763-A2 | COMPOUNDS AND METHODS OF TREATING OBESITY | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009109973-A2 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | FABP4, LIPC, GPR119 | CES2 107/4885MEN1 4525/4885FAAH 116/4885 |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | GPR119, FABP4, LIPC | CES2 139/4885MEN1 4530/4885FAAH 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.